Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Relapsed or Refractory B-cell Malignancies by Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells

NCT04008251 is registered in ClinicalTrials.gov with Wuhan Sian Medical Technology Co., Ltd as lead sponsor.

NCT NCT04008251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04008251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Relapsed or Refractory B-cell Malignancies by Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells
Lead sponsor
Wuhan Sian Medical Technology Co., Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
May 27, 2019
Completion date
December 31, 2022
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, b cell lymphoma